GO:0034436 glycoprotein transport: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034436 glycoprotein transport describes the directed movement of glycoproteins into, out of, or within cells by transporters or pores.
• Glycoprotein transport is mediated by ABC transporters such as P-glycoprotein (ABCB1) and by glycoprotein-associated amino acid exchangers.
• P-glycoprotein (ABCB1) efflux activity is a major determinant of drug pharmacokinetics and multidrug resistance in cancer.
• The mdr2 P-glycoprotein (ABCB4) transports phosphatidylcholine across the hepatocyte canalicular membrane, and its dysfunction causes PFIC3.
• Glycoprotein-associated amino acid exchangers (e.g., LAT1/SLC7A5) are involved in amino acid transport and are implicated in cancer metabolism.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of glycoprotein transport genes in disease and drug response.
Description
Glycoprotein transport (GO:0034436) is a biological process defined as the directed movement of a glycoprotein, a protein containing covalently bound glycose residues, into, out of, or within a cell, or between cells, by means of some agent such as a transporter or pore. This process is fundamental to cellular physiology because glycoproteins often function as transporters, receptors, or structural components whose localization determines signaling and metabolic outcomes. Researchers study glycoprotein transport to understand how cells regulate the distribution of glycosylated proteins and how defects in this process contribute to disease. The best-characterized glycoprotein transporters include P-glycoprotein (ABCB1), a member of the ATP-binding cassette (ABC) family that effluxes a wide range of substrates across the plasma membrane. Another example is mdr2 P-glycoprotein (ABCB4), which transports phosphatidylcholine across the hepatocyte canalicular membrane and is essential for bile formation. Glycoprotein-associated amino acid exchangers, such as LAT1 (SLC7A5) and LAT2 (SLC7A8), represent another class of glycoprotein transporters that mediate amino acid exchange and are implicated in cancer and immune cell function. Understanding glycoprotein transport is critical for drug development, as P-glycoprotein-mediated efflux limits oral bioavailability and brain penetration of many therapeutics. Moreover, genetic variants in glycoprotein transporters can alter drug response and disease susceptibility, making these proteins important targets for precision medicine. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:0034436, its molecular mechanisms, key genes, disease relevance, and experimental approaches.
glycoprotein transport At A Glance
| GO ID | GO:0034436 |
|---|---|
| GO term | glycoprotein transport |
| Ontology | biological_process |
| Synonym | none |
| Definition | The directed movement of a glycoprotein, a protein that contains covalently bound glycose (i.e. monosaccharide) residues, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| Major function | Translocation of glycosylated proteins across cellular membranes via transporters or pores |
| Related transporters | P-glycoprotein (ABCB1), mdr2 P-glycoprotein (ABCB4), glycoprotein-associated amino acid exchangers (e.g., LAT1/SLC7A5) |
| Cellular locations | Plasma membrane, canalicular membrane, intracellular vesicles |
| Disease relevance | Multidrug resistance in cancer, progressive familial intrahepatic cholestasis type 3 (PFIC3), drug-drug interactions |
What Is GO:0034436?
GO:0034436 glycoprotein transport is the directed movement of a glycoprotein, a protein that contains covalently bound glycose (monosaccharide) residues, into, out of, or within a cell, or between cells, by means of some agent such as a transporter or pore. This process encompasses the translocation of glycosylated proteins across membranes, their secretion, and their distribution between cellular compartments.
Why Is glycoprotein transport Important in Cell Biology?
Glycoprotein transport is essential for maintaining cellular homeostasis, as it controls the localization and activity of glycosylated proteins that function in nutrient uptake, drug efflux, and lipid transport. Dysregulation of glycoprotein transport contributes to major human diseases, including cancer multidrug resistance and cholestatic liver disease. Moreover, many therapeutic drugs are substrates or inhibitors of glycoprotein transporters, making this process a central consideration in pharmacology and drug development.
• P-glycoprotein (ABCB1) efflux activity determines the pharmacokinetics and brain penetration of many drugs.
• Glycoprotein-associated amino acid exchangers regulate amino acid homeostasis and are implicated in cancer metabolism.
• mdr2 P-glycoprotein (ABCB4) is required for hepatobiliary phosphatidylcholine transport, and its deficiency causes PFIC3.
• ABC transporters involved in lipid transport contribute to cellular lipid homeostasis and membrane asymmetry.
• Glycoprotein transport modulates drug-drug interactions and natural product-drug interactions.
• In vitro analysis of P-glycoprotein transport kinetics is critical for predicting clinical drug interactions.
• Microvilli morphology influences P-glycoprotein-mediated efflux activity, linking cell architecture to transport function.
• Bacterial multi-solute transporters provide evolutionary insights into glycoprotein transport mechanisms.
• Glycoprotein transport is a target for therapeutic intervention in multidrug-resistant cancers.
• Understanding glycoprotein transport informs the design of drugs with improved bioavailability and target specificity.
What Happens During glycoprotein transport?
Substrate recognition and binding
In simple terms: The transporter first recognizes and binds the glycoprotein cargo it will move.
Glycoprotein transport begins with the recognition of a glycosylated protein substrate by a transporter or pore complex. For ABC transporters such as P-glycoprotein (ABCB1), substrate binding occurs within the transmembrane domains, which accommodate a wide range of hydrophobic and amphipathic compounds. Glycoprotein-associated amino acid exchangers, such as LAT1 (SLC7A5), recognize specific amino acids with bulky side chains and mediate their exchange across the membrane. The specificity of substrate recognition determines which glycoproteins are transported and at what rate.
Conformational changes and translocation
In simple terms: The transporter changes shape to move the glycoprotein across the membrane.
Upon substrate binding, the transporter undergoes conformational changes that drive the translocation of the glycoprotein across the lipid bilayer. For P-glycoprotein, ATP binding and hydrolysis induce a conformational switch that opens the transporter to the extracellular side, releasing the substrate. Mechanistic kinetic modeling has been used to generate system-independent elementary rate constants for P-glycoprotein-mediated transport, revealing the importance of microvilli morphology on efflux activity. In the case of mdr2 P-glycoprotein (ABCB4), phosphatidylcholine is flipped from the inner to the outer leaflet of the canalicular membrane, a process essential for bile formation.
Energy coupling and regulation
In simple terms: The transport process uses energy and is tightly regulated by cellular signals.
Most glycoprotein transport processes are energy-dependent. ABC transporters such as P-glycoprotein and mdr2 P-glycoprotein utilize ATP hydrolysis to drive substrate translocation against concentration gradients. In contrast, glycoprotein-associated amino acid exchangers operate via facilitated diffusion, exchanging one amino acid for another without direct ATP consumption. The activity of these transporters is regulated at multiple levels, including transcriptional control, post-translational modifications, and membrane trafficking. For example, P-glycoprotein expression is induced by xenobiotics and chemotherapeutic agents, contributing to acquired drug resistance.
Vesicular and canalicular transport
In simple terms: Some glycoproteins are moved within the cell or secreted via vesicles.
In addition to plasma membrane transport, glycoprotein transport includes the movement of glycosylated proteins between intracellular compartments and their secretion into extracellular spaces. In hepatocytes, mdr2 P-glycoprotein (ABCB4) translocates phosphatidylcholine across the canalicular membrane, and this lipid is subsequently incorporated into bile. ABC transporters involved in lipid transport also participate in the trafficking of glycosphingolipids and cholesterol, influencing membrane composition and signaling. These vesicular and canalicular transport pathways are critical for organ-specific functions such as bile secretion and lipid homeostasis.
Bacterial multi-solute transporters
In simple terms: Bacteria use similar transport systems to move multiple solutes.
Bacterial multi-solute transporters provide evolutionary and mechanistic insights into glycoprotein transport. These transporters can recognize and translocate multiple structurally diverse substrates, a property shared with eukaryotic P-glycoprotein. Studies on bacterial transporters have revealed conserved mechanisms of substrate binding and conformational coupling that inform our understanding of human glycoprotein transport. This cross-species perspective highlights the ancient evolutionary origins of glycoprotein transport systems.
Key Genes Involved in GO:0034436 glycoprotein transport
The following genes encode transporters and related proteins that mediate or regulate glycoprotein transport (GO:0034436).
| Gene | Major Role | Research Relevance |
|---|---|---|
| ABCB1 | P-glycoprotein; ATP-dependent efflux transporter of xenobiotics and drugs | Multidrug resistance in cancer; drug pharmacokinetics and brain penetration |
| ABCB4 | mdr2 P-glycoprotein; phosphatidylcholine floppase in hepatocyte canalicular membrane | Progressive familial intrahepatic cholestasis type 3 (PFIC3); bile formation |
| SLC7A5 | LAT1; glycoprotein-associated amino acid exchanger for large neutral amino acids | Cancer metabolism; immune cell function; drug delivery |
| SLC7A8 | LAT2; glycoprotein-associated amino acid exchanger | Amino acid homeostasis; transport specificity |
| SLC3A2 | 4F2hc; glycoprotein subunit that associates with LAT1/LAT2 | Chaperone-like function for amino acid transporters |
| ABCB11 | BSEP; bile salt export pump | Cholestatic liver disease; bile acid transport |
| ABCG2 | BCRP; ATP-binding cassette efflux transporter | Drug resistance; urate transport |
| ABCC1 | MRP1; multidrug resistance-associated protein | Drug efflux; glutathione conjugate transport |
| SLC7A11 | xCT; cystine/glutamate exchanger | Redox homeostasis; cancer |
| SLC7A1 | CAT-1; cationic amino acid transporter | Arginine transport; immune function |
| SLC7A2 | CAT-2; cationic amino acid transporter | Nitric oxide synthesis; inflammation |
| SLC7A3 | CAT-3; cationic amino acid transporter | Neuronal arginine transport |
| SLC7A6 | y+LAT2; glycoprotein-associated amino acid exchanger | Amino acid transport in epithelial cells |
| SLC7A7 | y+LAT1; glycoprotein-associated amino acid exchanger | Lysinuric protein intolerance |
| SLC7A10 | ASC-1; alanine-serine-cysteine exchanger | Neurotransmitter transport; synaptic function |
| SLC7A11 | xCT; cystine/glutamate exchanger | Ferroptosis regulation; cancer therapy |
| ABCA1 | Cholesterol efflux transporter | HDL biogenesis; Tangier disease |
| ABCG1 | Cholesterol efflux transporter | Lipid homeostasis; atherosclerosis |
How Is glycoprotein transport Regulated?
Glycoprotein transport is regulated at multiple levels, including transcriptional induction by xenobiotics and chemotherapeutic agents, post-translational modifications such as phosphorylation, and membrane trafficking. P-glycoprotein expression and activity are modulated by intracellular signaling pathways and by the morphology of the plasma membrane, including microvilli density. In hepatocytes, mdr2 P-glycoprotein-mediated phosphatidylcholine transport is regulated by bile salt secretion and canalicular membrane composition. Additionally, glycoprotein-associated amino acid exchangers are regulated by substrate availability and by the expression of their associated glycoprotein subunits, such as 4F2hc (SLC3A2).
glycoprotein transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABCB1 | Multidrug resistance in cancer; altered drug pharmacokinetics | ABCB1 knockout and overexpression cell lines; point mutations to assess substrate specificity |
| ABCB4 | Progressive familial intrahepatic cholestasis type 3 (PFIC3) | Abcb4 knockout mice; knock-in of patient mutations in hepatocyte-like cells |
| SLC7A5 | Cancer metabolism; immune cell function | SLC7A5 knockout and overexpression in cancer cell lines; amino acid uptake assays |
| SLC7A7 | Lysinuric protein intolerance | SLC7A7 knockout cell models; point mutation knock-in to study transport defects |
| ABCG2 | Drug resistance; hyperuricemia | ABCG2 knockout and overexpression models; transport assays |
Multidrug resistance in cancer
Overexpression of P-glycoprotein (ABCB1) and other ABC transporters in cancer cells leads to efflux of chemotherapeutic agents, reducing intracellular drug concentrations and causing multidrug resistance. Mechanistic kinetic modeling of P-glycoprotein-mediated transport has provided system-independent rate constants that help predict drug efflux efficiency and guide inhibitor development. In vitro analysis of P-glycoprotein transport kinetics is therefore critical for evaluating potential resistance mechanisms and for screening P-glycoprotein inhibitors.
Progressive familial intrahepatic cholestasis type 3 (PFIC3)
Mutations in ABCB4, which encodes mdr2 P-glycoprotein, cause progressive familial intrahepatic cholestasis type 3 (PFIC3), a severe liver disease characterized by defective biliary phosphatidylcholine secretion. The mdr2 P-glycoprotein is essential for hepatobiliary lipid transport, and its dysfunction leads to bile duct damage and cholestasis. Research on mdr2 P-glycoprotein has elucidated the role of ABC transporters in lipid transport and membrane asymmetry.
Amino acid transport disorders and cancer metabolism
Glycoprotein-associated amino acid exchangers, such as LAT1 (SLC7A5) and LAT2 (SLC7A8), are implicated in cancer metabolism and immune cell function. Mutations in SLC7A7, which encodes y+LAT1, cause lysinuric protein intolerance, a rare inherited disorder of amino acid transport. These transporters are also being explored as targets for drug delivery and cancer therapy.
Drug-drug interactions and natural product interactions
Transporter-mediated natural product-drug interactions can significantly alter drug exposure and efficacy. P-glycoprotein and other glycoprotein transporters are key players in these interactions, as they modulate the absorption, distribution, and elimination of many drugs. Understanding glycoprotein transport is therefore essential for predicting clinical drug interactions and for optimizing therapeutic regimens.
From glycoprotein transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ABCB1 loss alter drug efflux and chemosensitivity? | ABCB1 knockout cancer cell lines (e.g., CRISPR-Cas9) |
| Do patient-specific ABCB4 mutations impair phosphatidylcholine transport? | Knock-in of ABCB4 mutations in hepatocyte-like cells or HepG2 cells |
| What is the substrate specificity of LAT1 (SLC7A5)? | SLC7A5 overexpression and point-mutation models with amino acid uptake assays |
| How does microvilli morphology affect P-glycoprotein efflux? | 3D SIM microscopy combined with mechanistic kinetic modeling in polarized epithelial cells |
| Can P-glycoprotein inhibitors reverse multidrug resistance? | ABCB1-overexpressing cell lines treated with inhibitors; transport kinetics assays |
| What is the role of mdr2 P-glycoprotein in bile formation? | Abcb4 knockout mice and canalicular membrane vesicle assays |
How to Study the glycoprotein transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Transport kinetics assay | Rate of substrate transport across membranes | P-glycoprotein efflux activity; drug interaction studies |
| Mechanistic kinetic modeling | Elementary rate constants for transport | System-independent comparison of P-glycoprotein function |
| 3D SIM microscopy | Transporter localization and membrane morphology | Microvilli influence on efflux activity |
| CRISPR-Cas9 knockout | Loss-of-function phenotype | Causal role of glycoprotein transporters in drug resistance |
| CRISPR-Cas9 knock-in | Effect of patient-specific mutations | ABCB4 mutations in PFIC3 |
| Amino acid uptake assay | Transport activity of amino acid exchangers | LAT1/LAT2 substrate specificity |
| Vesicle transport assay | Translocation of lipids or proteins across membrane vesicles | mdr2 P-glycoprotein-mediated phosphatidylcholine transport |
| Natural product-drug interaction assay | Modulation of transporter-mediated drug transport | Herbal-drug interaction screening |
Transport kinetics assays
In vitro transport kinetics assays are used to measure the rate of glycoprotein transport across cell monolayers or membrane vesicles. These assays typically employ fluorescent or radiolabeled substrates and are analyzed using kinetic models to derive parameters such as Km and Vmax. Mechanistic kinetic modeling can generate system-independent elementary rate constants for P-glycoprotein-mediated transport, enabling comparison across experimental systems.
3D SIM microscopy
Three-dimensional structured illumination microscopy (3D SIM) allows visualization of transporter localization and membrane morphology at high resolution. This technique has been used to elucidate the importance of microvilli morphology on P-glycoprotein-mediated efflux activity, revealing that cell surface architecture directly influences transport efficiency.
CRISPR-Cas9 knockout and knock-in
CRISPR-Cas9 genome editing enables the generation of knockout and knock-in cell models to study glycoprotein transport genes. Knockout models eliminate transporter expression to assess loss-of-function phenotypes, while knock-in models introduce specific patient mutations to study their impact on transport activity. These approaches provide causal insights into the role of glycoprotein transporters in disease and drug response.
Amino acid uptake and efflux assays
Amino acid uptake and efflux assays are used to measure the activity of glycoprotein-associated amino acid exchangers such as LAT1 (SLC7A5) and LAT2 (SLC7A8). These assays typically use radiolabeled or fluorescent amino acid analogs and can be performed in cell lines overexpressing or lacking specific transporters. Such assays are essential for characterizing substrate specificity and transport kinetics.
How CRISPR Can Be Used to Study GO:0034436 glycoprotein transport
Knockout
CRISPR-Cas9 knockout of glycoprotein transport genes, such as ABCB1 or SLC7A5, eliminates transporter expression and allows assessment of loss-of-function phenotypes. For example, ABCB1 knockout cancer cell lines show increased sensitivity to chemotherapeutic drugs that are P-glycoprotein substrates. Knockout models are essential for establishing causal relationships between transporter activity and drug response or disease progression.
Point Mutation
CRISPR-Cas9 point mutation knock-in introduces specific amino acid substitutions into glycoprotein transporter genes to study their impact on substrate binding, transport kinetics, and drug resistance. For instance, point mutations in ABCB4 identified in PFIC3 patients can be modeled in hepatocyte-like cells to assess phosphatidylcholine transport defects. Such models provide mechanistic insights into how genetic variants alter transporter function.
Knock-in
CRISPR-Cas9 knock-in can be used to insert reporter tags or patient-derived mutations into endogenous glycoprotein transporter loci. Tagged knock-in models enable real-time tracking of transporter localization and trafficking in live cells. Knock-in of disease-associated mutations, such as those in ABCB4, allows functional characterization of variants in a physiologically relevant context.
Overexpression
CRISPR activation or lentiviral overexpression of glycoprotein transporters, such as ABCB1 or SLC7A5, is used to study gain-of-function phenotypes and drug resistance mechanisms. Overexpression models are valuable for screening transporter inhibitors and for assessing substrate specificity. For example, ABCB1-overexpressing cell lines are widely used to evaluate P-glycoprotein inhibitors as potential chemosensitizers.
How EDITGENE Supports glycoprotein transport Research
Researchers studying glycoprotein transport-related genes often need to determine whether a candidate gene is causally involved in transport activity, drug resistance, or disease pathogenesis. EDITGENE provides comprehensive CRISPR gene editing services to generate knockout, point-mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics support, enabling rigorous functional studies of glycoprotein transport genes.
Contact EDITGENE today to design your custom CRISPR model for glycoprotein transport research.
Frequently Asked Questions About glycoprotein transport
What is glycoprotein transport (GO:0034436)?
Glycoprotein transport is the directed movement of a glycoprotein, a protein with covalently bound monosaccharide residues, into, out of, or within a cell, or between cells, by means of a transporter or pore.
What genes are involved in glycoprotein transport?
Key genes include ABCB1 (P-glycoprotein), ABCB4 (mdr2 P-glycoprotein), SLC7A5 (LAT1), SLC7A8 (LAT2), and SLC3A2 (4F2hc), among others.
How is glycoprotein transport regulated?
It is regulated by transcriptional induction, post-translational modifications, membrane trafficking, and substrate availability.
What diseases are associated with glycoprotein transport defects?
Diseases include multidrug resistance in cancer, progressive familial intrahepatic cholestasis type 3 (PFIC3), and lysinuric protein intolerance.
What is the role of P-glycoprotein in drug resistance?
P-glycoprotein (ABCB1) effluxes chemotherapeutic agents, reducing intracellular drug concentrations and causing multidrug resistance.
How can I study glycoprotein transport in the lab?
Common methods include transport kinetics assays, 3D SIM microscopy, CRISPR knockout/knock-in, and amino acid uptake assays.
What is mdr2 P-glycoprotein and what does it do?
mdr2 P-glycoprotein (ABCB4) transports phosphatidylcholine across the hepatocyte canalicular membrane and is essential for bile formation.
What are glycoprotein-associated amino acid exchangers?
They are transporters such as LAT1 (SLC7A5) and LAT2 (SLC7A8) that exchange amino acids across membranes and are involved in cancer metabolism.
Can CRISPR be used to study glycoprotein transport?
Yes, CRISPR-Cas9 knockout, point mutation, knock-in, and overexpression models are widely used to dissect glycoprotein transport gene function.
What are natural product-drug interactions involving glycoprotein transporters?
Natural products can modulate glycoprotein transporters such as P-glycoprotein, altering drug absorption and efficacy.
Conclusion
Glycoprotein transport (GO:0034436) is a fundamental biological process that governs the movement of glycosylated proteins across cellular membranes, with critical roles in drug disposition, lipid homeostasis, and amino acid transport. Dysregulation of this process contributes to major human diseases, including cancer multidrug resistance and cholestatic liver disease. Continued research using CRISPR-based models and advanced imaging techniques will further elucidate the molecular mechanisms and therapeutic potential of glycoprotein transport.
References
- 1. Verrey F et al.. 2000. Glycoprotein-associated amino acid exchangers: broadening the range of transport specificity.. Pflugers Arch 440(4):503-12 PMID: 10958334
- 2. Saaby L et al.. 2017. A Critical View on In Vitro Analysis of P-glycoprotein (P-gp) Transport Kinetics.. J Pharm Sci 106(9):2257-2264 PMID: 28438535
- 3. Ellens H et al.. 2018. Mechanistic kinetic modeling generates system-independent P-glycoprotein mediated transport elementary rate constants for inhibition and, in combination with 3D SIM microscopy, elucidates the importance of microvilli morphology on P-glycoprotein mediated efflux activity.. Expert Opin Drug Metab Toxicol 14(6):571-584 PMID: 29788828
- 4. Slotboom DJ et al.. 2020. Bacterial multi-solute transporters.. FEBS Lett 594(23):3898-3907 PMID: 32810294
- 5. Elferink RP et al.. 1997. Hepatic canalicular membrane 1: The role of mdr2 P-glycoprotein in hepatobiliary lipid transport.. FASEB J 11(1):19-28 PMID: 9034162
- 6. Borst P et al.. 2000. ABC transporters in lipid transport.. Biochim Biophys Acta 1486(1):128-44 PMID: 10856718
- 7. Verrey F et al.. 1999. New glycoprotein-associated amino acid transporters.. J Membr Biol 172(3):181-92 PMID: 10568788
- 8. Bi Y et al.. 2023. Transporter-mediated Natural Product-Drug Interactions.. Planta Med 89(2):119-133 PMID: 35304735
